B. Barlogie, Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients, Blood, vol.85, issue.2, pp.588-96, 1995.

A. Palumbo and K. Anderson, Multiple Myeloma, New England Journal of Medicine, vol.364, issue.11, pp.1046-1060, 2011.
DOI : 10.1056/NEJMra1011442

URL : https://hal.archives-ouvertes.fr/hal-01282339

D. Esseltine, A. Cakana, K. Liu, W. Deraedt, H. Van-de-velde et al., Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy; analysis of the Phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone, Blood, vol.116, pp.3743-50, 2010.

J. Harousseau, M. Attal, H. Avet-loiseau, G. Marit, D. Caillot et al., Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial, Journal of Clinical Oncology, vol.28, issue.30, pp.4621-4629, 2010.
DOI : 10.1200/JCO.2009.27.9158

F. Arriba, N. Gutiérrez, M. Martín-ramos, M. Cibeira, M. Mateos et al., Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study, Blood, vol.120, issue.8, 2012.

P. Moreau, Bortezomib-Based Versus Non-bortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials, J Clin Oncol, issue.26, pp.31-3279, 2013.

W. Esmo-guidelines and . Group, Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up, Ann Oncol, vol.24, pp.133-137, 2013.

X. Leleu, G. Fouquet, B. Hebraud, M. Roussel, D. Caillot et al., Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma, Leukemia, vol.366, issue.11, pp.2242-2244, 2013.
DOI : 10.1056/NEJMoa1114138

T. Mcelwain and R. Powles, HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA, The Lancet, vol.322, issue.8354, pp.822-824, 1983.
DOI : 10.1016/S0140-6736(83)90739-0

J. Child, G. Morgan, F. Davies, R. Owen, S. Bell et al., High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma, New England Journal of Medicine, vol.348, issue.19, pp.1875-1883, 2003.
DOI : 10.1056/NEJMoa022340

W. Bensinger, J. Dipersio, and J. Mccarty, Improving stem cell mobilization strategies: future directions, Bone Marrow Transplantation, vol.93, issue.3, pp.181-95, 2009.
DOI : 10.1016/j.bbmt.2007.03.007

URL : http://www.nature.com/bmt/journal/v43/n3/pdf/bmt2008410a.pdf

M. Mohty and J. Harousseau, Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers, Haematologica, vol.99, issue.3, pp.408-424, 2014.
DOI : 10.3324/haematol.2013.096149

M. Mohty, K. Hübel, N. Kröger, M. Aljurf, J. Apperley et al., Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation, Bone Marrow Transplantation, vol.54, issue.7, pp.865-72, 2014.
DOI : 10.1038/bmt.2011.82

G. Bridger, AMD3100 plus G-CSF can successfully mobilize CD341 cells from

. Hodgkin-'s-lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data, Bone Marrow Transplant, vol.41, issue.4, pp.331-338, 2008.

J. Mccarty, G. Bridger, and C. G. , 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma, J Clin Oncol, vol.27, issue.28, pp.4767-4773, 2009.

G. Plerixafor, versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma, Blood, vol.113, issue.23, pp.5720-5726, 2009.

A. Addio, A. Curti, N. Worel, K. Douglas, M. Motta et al., The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF, Bone Marrow Transplantation, vol.45, issue.3, pp.356-363, 2011.
DOI : 10.1038/sj.bmt.1703729

C. Abboud, K. Stockerl-goldstein, D. Sempek, A. Smith, and J. Dipersio, Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation, Biol Blood Marrow Transplant, vol.14, issue.9, pp.1045-1056, 2008.

E. Jantunen, V. Varmavuo, A. Juutilainen, T. Kuittinen, E. Mahlamäki et al., Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: Implications for pre-emptive plerixafor use, Annals of Hematology, vol.15, issue.7, pp.1073-1079, 2012.
DOI : 10.3109/10428194.2011.578312

C. Chabannon, F. Bijou, J. Miclea, N. Milpied, J. Grouin et al., A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the ???on-demand??? scheme of administration at French autologous hematopoietic stem cell transplant programs, Transfusion, vol.49, issue.9, pp.2149-2157, 2015.
DOI : 10.1038/bmt.2014.39

J. Cheng, M. Schmitt, P. Wuchter, E. Buss, M. Witzens-harig et al., Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma, Transfusion, vol.14, issue.2, pp.275-283, 2015.
DOI : 10.3109/14653249.2011.652733

N. Worel, G. Fritsch, H. Agis, A. Böhm, G. Engelich et al., Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure, Journal of Clinical Apheresis, vol.53, issue.2, pp.1-11, 2017.
DOI : 10.1111/j.1537-2995.2012.03848.x

N. Benyamini, I. Avivi, E. Dann, T. Zuckerman, N. Lavi et al., Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone, Annals of Hematology, vol.26, issue.Suppl 6, pp.461-467, 2017.
DOI : 10.1038/leu.2011.197

J. Zhao, G. Edgren, and S. Stanworth, Is there a standard-of-care for transfusion support of patients with haematological malignancies?, Current Opinion in Hematology, vol.24, issue.6, pp.1-6, 2017.
DOI : 10.1097/MOH.0000000000000377

J. Kiss, W. Rybka, A. Winkelstein, M. Silverman, J. Lister et al., Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation, Bone Marrow Transplantation, vol.19, issue.4, pp.303-313, 1997.
DOI : 10.1038/sj.bmt.1700671

S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-stella, Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy, Journal of Clinical Oncology, vol.18, issue.6, pp.1360-77, 2000.
DOI : 10.1200/JCO.2000.18.6.1360

P. Duggan, D. Guo, J. Luider, I. Auer, J. Klassen et al., Predictive factors for long-term engraftment of autologous blood stem cells, Bone Marrow Transplantation, vol.4, issue.12, pp.1299-304, 2000.
DOI : 10.1038/2023

C. Solá, P. Maroto, R. Salazar, R. Mesía, L. Mendoza et al., Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy, Hematology, vol.84, issue.5, pp.195-209, 1999.
DOI : 10.1200/JCO.1995.13.8.1922

E. Jantunen and S. Fruehauf, Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens, Bone Marrow Transplantation, vol.14, issue.5, pp.627-662, 2011.
DOI : 10.3109/10428190009065829

F. Saraceni, N. Shem-tov, A. Olivieri, and A. Nagler, Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective, Bone Marrow Transplantation, vol.112, issue.7, pp.886-91, 2015.
DOI : 10.1182/blood-2007-12-130179

URL : http://www.nature.com/bmt/journal/v50/n7/pdf/bmt2014330a.pdf

D. Hiwase, S. Hiwase, M. Bailey, G. Bollard, and A. Schwarer, Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.14, issue.1, pp.116-140, 2008.
DOI : 10.1016/j.bbmt.2007.08.051

L. Porrata, M. Gertz, D. Inwards, M. Litzow, M. Lacy et al., Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma, Blood, vol.98, issue.3, pp.579-85, 2001.
DOI : 10.1182/blood.V98.3.579

URL : http://www.bloodjournal.org/content/bloodjournal/98/3/579.full.pdf